Evidence map›Paper›PMID 41737449›Full record

ReviewRSC advances2026

Carbon quantum dots as transcutaneous drug carriers: mechanisms, challenges and prospects.

Veena Venugopal, B Siva Kumar, S Giridhar Reddy, Sai Manohar Thota

Abstract readReview
In one paragraph

Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Veena VenugopalDepartment of Physical Sciences, Amrita School of Engineering, Amrita Vishwa Vidyapeetham Bengaluru 560035 India b_sivakumar@blr.amrita.edu.ORCID https://orcid.org/0009-0003-5308-5669
B Siva KumarDepartment of Physical Sciences, Amrita School of Engineering, Amrita Vishwa Vidyapeetham Bengaluru 560035 India b_sivakumar@blr.amrita.edu.ORCID https://orcid.org/0000-0003-1257-4899
S Giridhar ReddyDepartment of Physical Sciences, Amrita School of Engineering, Amrita Vishwa Vidyapeetham Bengaluru 560035 India b_sivakumar@blr.amrita.edu.ORCID https://orcid.org/0000-0001-5151-5205
Sai Manohar ThotaMolecular and Cellular Biology, Baylor College of Medicine Houston TX USA.ORCID https://orcid.org/0000-0003-1710-5645

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Incorporation of nanoparticles has revolutionized drug delivery by optimizing the targeted transport of drugs, boosting the solubility and stability of pharmaceuticals, and facilitating precise, controlled release. These breakthroughs have made a significant contribution, especially in personalized medicine for many health issues. A variety of nanoparticles, including lipid-based systems, polymeric carriers, dendrimers, metallic nanoparticles, and nanogels, have been employed in drug delivery to improve drug solubility, protect active compounds from degradation, and achieve controlled release. Quantum dots are zero dimensional nanoparticles distinguished by intrinsic fluorescence, in particular carbon quantum dots allow for real-time imaging, superior biocompatibility, and antimicrobial properties rendering them highly adaptable for sophisticated therapeutic and diagnostic uses. Transcutaneous drug delivery devices offer a non-invasive approach for administering medications through the skin, enabling drugs to bypass the gastrointestinal tract and first-pass metabolism thereby improving bioavailability, and promoting enhanced patient compliance. Nanoparticles, particularly those sized between 1 and 10 nm in all dimensions, significantly enhance skin penetration, thereby improving drug delivery to deeper tissues, thus making carbon dots an ideal candidate as a nanocarrier in the transcutaneous system. A focused review on carbon quantum dots as novel nanocarriers to overcome present obstacles in transcutaneous drug administration is critically presented.

Identifiers

PMID41737449
PMCPMC12927579

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.